Leukocytapheresis is effective in inducing but not in maintaining remission in ulcerative colitis

Journal of Clinical Gastroenterology

Volumn 39, Issue 10, 2005, Pages 886-890

  Honma, Terasu ^a,b   Sugimura, Kazuhito ^a   Asakura, Hitoshi ^a   Matsuzawa, Jun ^a   Suzuki, Kohji ^a   Kobayashi, Masaaki ^a   Aoyagi, Yutaka ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

Leukocytapheresis; Maintenance; Therapy; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ADULT; AGRANULOCYTOSIS; ALOPECIA; ARTICLE; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; CYTAPHERESIS; DOSE TIME EFFECT RELATION; DRUG MEGADOSE; DRUG RESISTANCE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; LEUKAPHERESIS; LEUKOCYTAPHERESIS; MAINTENANCE THERAPY; MALE; PANCREATITIS; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKAPHERESIS; MALE; MIDDLE AGED; PREDNISOLONE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 27144476539     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000180638.59140.c5     Document Type: Article

References (27)

1. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2000;51:289-298.
2. Anezaki K, Asakura H, Honma T, et al. Correlations between interleukin 8, and myeloperoxidase or luminol-dependent chemiluminescence in inflamed mucosa of ulcerative colitis. Intern Med. 1998;37:253-258.
3. Suzuki K, Sugimura K, Hasegawa K, et al. Activated platelets in ulcerative colitis enhance the production of reactive oxygen species by polymorphonuclear leukocytes. Scand J Gastroenterol. 2001;36:1301-1306.
4. Roberts WG, Simon TJ, Bertin RG, et al. Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterotogy. 1997;112:725-732.
5. Kombluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology practice parameters committee. Am J Gastroenterol. 1997;92:204-211.
6. Gassull MA, Esteve M. Steroid unresponsiveness in inflammatory bowel disease. In: Bayless TM, Hanauer SB, eds. Advanced Therapy of Inflammatory Bowel Disease. Hamilton, Decker, 2001:133-137.
7. Sawada K, Ohnishi K, Fukui S, et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol. 1995;30:322-329.
8. Ayabe T, Ashida T, Taniguchi M, et al. A pilot study of centrifugal leukocyte apheresis for corticosteroid-resistant active ulcerative colitis. Intern Med. 1997;36:322-326.
9. Shimoyama T, Sawada K, Hiwatashi N, et al. Safety and efficacy of granulocyte and monocyte absorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apheresis. 2001;16:1-9.
10. Sawada K, Muto T, Shimoyama T, et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des. 2003;9:307-321.
11. Truelove SC, Witts LJ. Cortisone in ulcerative colitis. BMJ. 1955;1:1041-1048.
12. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841-1845.
13. Maida E, Hocker P, Mann E. Long-term lymphocytapheresis therapy in multiple sclerosis: preliminary observations. Eur Neurol. 1986;25:225-232.
14. Miller FW, Lleitman SF, Cronin ME, et al. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. N Engl J Med. 1992;326:1380-1384.
15. Wallace D, Goldfinger D, Lowe C, et al. A double-blind, controlled study of lymphoplasmapheresis versus sham apheresis in rheumatoid arthritis. N Engl J Med. 1982;306:1406-1410.
16. Lerebours E, Bussel A, Modigliani R, et al. Treatment of Crohn's disease by lymphocyte apheresis: a randomized controlled trial. Gastroenterology. 1994;107:357-361.
17. Ardizzone S, Molteni F, Imbesi V, et al. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol. 1997;25:330-333.
18. Strober W, Kelsall B, Fuss IJ, et al. Reciprocal IFN-γ and TGF-β responses regulate the occurrence of mucosal inflammation. Immunol Today. 1997;18:61-66.
19. Stallmach A, Strober W, MacDonald TT, et al. Induction and modulation of gastrointestinal inflammation. Immunol Today. 1998;19:438-441.
20. Toms C, Powrie F. Control of intestinal inflammation by regulatory T cells. Microbes Infect. 2001;3:929-935.
21. Chey WY, Hussain A, Ryan C, et al. Infliximab for refractory ulcerative colitis. Am J Gastroenterol. 2001;96:2373-2381.
22. van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease: Crohn's Disease Study Group. Gastroenterology. 1997;113:383-389.
23. Hanai H, Watanabe F, Takeuchi K, et al. Leukocyte adsorptive for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol. 2003;1:28-35.
24. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495-549.
25. Schwartz DA, Sandborn WJ. Chronic pouchitis. In: Bayless TM, Hanauer SB, eds. Advanced Therapy of Inflammatory Bowel Disease. Hamilton, Decker, 2001:219-223.
26. + T T cells in the inflamed mucosa of ulcerative colitis. Scand J Gastroenterol. 2000;35:1278-1283.
27. Neurath MF, Finotto S, Fuss IJ, et al. Regulation of T cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. Trends Immunol. 2001;22:21-26.